References 1. Treatment Action Campaign. Competition Commission Complaint Against GlaxoSmithKline and Boehringer Ingelheim. 16 October 2003. Available online: http://www.tac.org.za/Documents/DrugCompaniesCC/DrugCompaniesCC.htm 2. Kim, J. We could have done more. Presentation at the Kennedy School of Government, November 30, 2000. 3. Public Citizen. (2001). Rx R&D Myths: The Case Against the Drug Industry's R&D "Scare Card". Available online: http://www.citizen.org/publications/release.cfm?ID=7065 4. Families USA. (2002). Profiting from Pain: Where Prescription Drugs Dollars Go. Available online: http://www.familiesusa.org/ 5. World Trade Organization. Declaration on the TRIPS agreement and public health. in Doha Ministerial Conference. 2001. Doha, Qatar: World Trade Organization. 6. http://lists.essential.org/pipermail/ip-health/2003-December/005716.html 7. Robbins, G.K. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. The New England Journal of Medicine, 349(24): 2293- 2303. 8. Rajkumar, R. Between trade and treatment. The New Republic, in review. 9. http://www.zmag.org/content/showarticle.cfm?SectionID=13&ItemID=4098 10. http://www.zmag.org/content/showarticle.cfm?SectionID=13&ItemID=3149 11. http://www.zmag.org/content/showarticle.cfm?SectionID=2&ItemID=3021 12. Bello, W., S. Cunningham, and L.K. Poh, A Siamese Tragedy: Development and Disintegration in Modern Thailand. 1998, London: Zed Books. 13. Kim, J.Y., et al., eds. Dying for Growth: Global Inequality and the Health of the Poor. 2000, Common Courage Press: Monroe. 14. Zimmet, P., Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted? Journal of Internal Medicine, 2000. 247: p. 301-10. 15. http://www.zmag.org/content/showarticle.cfm?SectionID=2&ItemID=3988